EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heterologous Antigen Regimen and Bicistronic DNA Vaccination Targeting HPV16 E5 and E7 Oncoproteins: Immunoinformatics and Preclinical Antitumor Efficacy

Ingrid Andrêssa de Moura iD, Karina Mayumi Tani Bezerra de Melo iD, Lígia Rosa Sales Leal, Maria da Conceição Viana Invenção iD, Larissa Silva de Macêdo iD, Samara Sousa de Pinho iD, Lucas Matheus Barreto Santana, Julia Dias da Silva, Tiago Henrique Dos Santos Souza iD, Julliano Matheus de Lima Maux iD, Jacinto da Costa Silva Neto iD, Anna Jéssica Duarte Silva iD und 1 weitere

Molecules · 2026

DOI: 10.3390/molecules31193442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Ingrid Andrêssa de Moura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil. Hauptthemen laut MEDLINE: Vaccines, DNA, Papillomavirus E7 Proteins, Oncogene Proteins, Viral, Human papillomavirus 16. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Ciência e Tecnologia de Pernambuco, Conselho Nacional de Desenvolvimento Científico e Tecnológico, FACEPE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent infection with high-risk human papillomavirus, particularly HPV16, is a major cause of cervical cancer and orogenital malignancies. Therapeutic DNA vaccines targeting viral oncoproteins represent a promising strategy to induce antitumor immune responses. However, the impact of antigen combinations in bicistronic vectors and the immunization sequence on therapeutic efficacy remains poorly understood. Thus, this study aimed to characterize in silico previously described E5CP and E7CP vaccines, develop a new bicistronic construct, and evaluate its antitumor efficacy under different immunization regimens in vivo. The constructs were initially characterized regarding predicted physicochemical, immunological, and structural properties, followed by molecular confirmation of plasmid construction and qualitative assessment of transcript detection after transient transfection. In vivo, C57BL/6 mice bearing C3 tumors were immunized with five different regimens combining the monocistronic or bicistronic constructs. At the endpoint, tumors and spleens were collected for histopathological and immunological analyses. The results showed that regimens using the bicistronic construct or including E5 in the first dose were associated with lower mean tumor volumes or delayed tumor growth compared to the control groups. Histopathological and immunophenotypic changes were variable among regimens, and an exploratory analysis suggested an association between lower nitric oxide levels and smaller tumor volumes. Therefore, the order of antigen administration and the use of bicistronic constructs warrant further investigation as strategies that could be optimized to improve the therapeutic efficacy of HPV DNA vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, DNAPapillomavirus E7 ProteinsOncogene Proteins, ViralHuman papillomavirus 16Papillomavirus VaccinesCancer VaccinesPapillomavirus InfectionsAnimalsMiceFemaleImmunoinformaticsMice, Inbred C57BLViroporin ProteinsHumansVaccinationCell Line, Tumor

Stichwörter der Autor:innen

E5 oncoproteinE7 oncoproteinHPV16histopathologymurine modelnitric oxideprime–boost immunizationtherapeutic DNA vaccine

Substanzen

Vaccines, DNAPapillomavirus E7 Proteinsoncogene protein E7, Human papillomavirus type 16Oncogene Proteins, Viraloncogene protein E5, Human papillomavirus type 16Viroporin ProteinsPapillomavirus VaccinesCancer Vaccines

Autor:innen und Institutionen

  • Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil.
  • Department of Virology and Experimental Therapy, Fundação Oswaldo Cruz/Fiocruz, Recife 50740-465, Brazil.
  • Department of Biophysics and Radiobiology, Federal University of Pernambuco, Recife 50670-901, Brazil.
  • Laboratory of Cytological and Molecular Research-LPCM, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil.

ORCID-Profile: Ingrid Andrêssa de Moura, Karina Mayumi Tani Bezerra de Melo, Maria da Conceição Viana Invenção, Larissa Silva de Macêdo, Samara Sousa de Pinho, Tiago Henrique Dos Santos Souza, Julliano Matheus de Lima Maux, Jacinto da Costa Silva Neto, Anna Jéssica Duarte Silva, Antonio Carlos de Freitas

Förderung

  • Fundação de Amparo à Ciência e Tecnologia de Pernambuco
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • FACEPE
  • CNPq

Zitieren

APA

Moura, I. A., Melo, K. M. T. B., Leal, L. R. S., Invenção, M. D. C. V., de Macêdo, L. S., Pinho, S. S., Santana, L. M. B., da Silva, J. D., Souza, T. H. D. S., Maux, J. M. L., Silva Neto, J. D. C., Silva, A. J. D., & de Freitas, A. C. (2026). Heterologous Antigen Regimen and Bicistronic DNA Vaccination Targeting HPV16 E5 and E7 Oncoproteins: Immunoinformatics and Preclinical Antitumor Efficacy. Molecules. https://doi.org/10.3390/molecules31193442

Vancouver

Moura IA, Melo KMTB, Leal LRS, Invenção MDCV, de Macêdo LS, Pinho SS, et al. Heterologous Antigen Regimen and Bicistronic DNA Vaccination Targeting HPV16 E5 and E7 Oncoproteins: Immunoinformatics and Preclinical Antitumor Efficacy. Molecules. 2026. doi:10.3390/molecules31193442

BibTeX
@article{Moura2026,
  author = {Moura, Ingrid Andrêssa de and Melo, Karina Mayumi Tani Bezerra de and Leal, Lígia Rosa Sales and Invenção, Maria da Conceição Viana and de Macêdo, Larissa Silva and Pinho, Samara Sousa de and Santana, Lucas Matheus Barreto and da Silva, Julia Dias and Souza, Tiago Henrique Dos Santos and Maux, Julliano Matheus de Lima and Silva Neto, Jacinto da Costa and Silva, Anna Jéssica Duarte and de Freitas, Antonio Carlos},
  title = {Heterologous Antigen Regimen and Bicistronic DNA Vaccination Targeting HPV16 E5 and E7 Oncoproteins: Immunoinformatics and Preclinical Antitumor Efficacy},
  journal = {Molecules},
  year = {2026},
  doi = {10.3390/molecules31193442}
}
Kostenlos starten →